ClinicalTrials.gg
CompletedNCT01127217Updated Sep 14, 2010

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

A Phase 3 interventional study of amlodipine/losartan and amlodipine in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-14.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
103rd of 186
149 · median 180
Started
2009
with 12 others
Phase 3
69 of 187
2 open now
Registered
93rd of 187
by date
Lead sponsor
6 of 187
Hanmi Pharmaceutical Company Limited

Among the 187 studies testing amlodipine in Hypertension, this one is the 103rd largest by enrollment of the 186 interventional ones that give a count, is one of 13 that started in 2009, is one of 69 in phase 3, and was the 93rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and amlodipine monotherapy for treatment of Stage 2 hypertensive patients.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • amlodipine
  • losartan
  • hypertension
  • stage 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 aged or over
  • Patients with blood pressure measured at Visit 1; MSSBP≤180mmHg and MSDBP≤110 mmHg if on anti-hypertensive drugs, 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg if not on anti-hypertensive drugs
  • Patients with blood pressure measured at Visit 2 were 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg

Exclusion criteria

Exclusion Criteria:

  • Inability to stop all prior anti-hypertensive drugs safely during wash out period of 3 to 7 days
  • ≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening
  • History of to dihydropyridines, angiotensin II receptor blockers or thiazide diuretics
  • Secondary hypertension or suspected to be
  • Continuously took medicinal drugs that might affect blood pressure rather than anti-hypertensive drugs more than 3 months
  • Type 2 diabetes mellitus which is not controlled or with type 1 diabetes mellitus
  • History of severe neurovascular disease, severe heart disease
  • Known as moderate or malignant retinopathy.
  • Renal diseases; serum creatinine ≥ 2mg/dl
  • Hepatic diseases; increase in or AST ≥ 2xUNL
  • Anuria
  • Hyponatremia/hypokalemia or hypercalcemia
  • Active Gout
  • Surgical or medical diseases which might significantly change ADME of medicines
  • History of malignant tumor
  • diseases
  • History of alcohol or drug abuse
  • Positive to pregnancy test, nursing mother, woman with an intention of pregnancy
  • Considered inappropriate to participate in the clinical trial with any reason, based on investigator's decision

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
149 participants (actual)

Study arms

  • Experimental
    amlodipine/losartan

    Drug: amlodipine/losartan

  • Active comparator
    amlodipine

    Drug: amlodipine

Interventions

  • Drugamlodipine/losartan

    Drug pages: Amlodipine · Losartan

    amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)

    Also known as: amosartan

  • amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)

    Also known as: amodipin(amlodipine camsylate)

06

What researchers measure

Primary outcomes

  1. Change from baseline in MSSBP

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change from baseline in MSSBP

    Time frame: Baseline, Week 2 and 8

  2. Change from baseline MSDBP

    Time frame: Baseline, Week 2, 6, and 8

  3. Blood pressure responder rate

    Rate of patients who achieved target blood pressure (MSSBP \< 140 mmHg or MSDBP \< 90 mmHg), or MSSBP decrease \> 20 mmHg from baseline or MSDBP decrease \> 10 mmHg from baseline.

    Time frame: Baseline, Week 2, 6, 8

07

Study locations

1 site
  • 8 Sites
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kim SH, Ryu KH, Lee NH, Kang JH, Kim WS, Park SW, Lee HY, Kim JJ, Ahn YK, Suh SY. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Res Notes. 2011 Oct 28;4:461. doi: 10.1186/1756-0500-4-461. PubMed 22035131 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2010
First posted
May 20, 2010
Start
May 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Last update
Sep 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01127217
First posted
May 20, 2010
Start date
May 2009
Primary completion
Mar 2010
Completion
Mar 2010
Last update
Sep 14, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Losartan

Start the discussion